Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral SclerosisTerminated
NCT03757351Phase 1Updated Sep 22, 2025
Sponsor: Sanofi
Amyotrophic Lateral Sclerosis
United States, Netherlands
Single Dose Comparability Study of New and Current Dupilumab Drug Products Subcutaneously Administered in Healthy AdultsCompleted
NCT05976386Phase 1Updated Sep 19, 2025
Sponsor: Sanofi
Healthy Volunteers
United States
Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in ThaïlandCompleted
NCT04594551Phase 3Updated Sep 19, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Rabies (Healthy Volunteers)
Thailand
A Pharmacokinetic and Tolerability Study of Fexinidazole in a Single Oral Dose in Adult Participants With Mild and Moderate Hepatic ImpairmentCompleted
NCT05607173Phase 1Updated Sep 19, 2025
Sponsor: Sanofi
Hepatic Function Abnormal
Bulgaria, France
Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in ThaïlandCompleted
NCT04478084Phase 3Updated Sep 19, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Rabies (Healthy Volunteers)
Thailand
Performance of the Echopen Probe in Its Clinical Use for Pregnancy Follow-up in SenegalCompleted
NCT05765539NAUpdated Sep 19, 2025
Sponsor: echOpen Factory
Pregnancy Related
Senegal
A PK Comparability Study of Two Different Amlitelimab Drug Products in Healthy ParticipantsCompleted
NCT05796479Phase 1Updated Sep 19, 2025
Sponsor: Sanofi
Healthy Volunteers
United States
FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney DiseaseCompleted
NCT01220843Phase 3Updated Sep 19, 2025
Sponsor: Centre Hospitalier Universitaire, Amiens
Chronic Renal Failure
France
Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia ACompleted
NCT05042440Phase 1Updated Sep 18, 2025
Sponsor: Sanofi
Hemophilia A
Bulgaria
Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in AdultsCompleted
NCT03965962Phase 3Updated Sep 18, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Rabies (Healthy Volunteers)
France
A Single Ascending Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of SAR441566 in Healthy Adult Japanese Male Participants.Completed
NCT05858788Phase 1Updated Sep 18, 2025
Sponsor: Sanofi
Rheumatoid Arthritis
United States
Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast CancerTerminated
NCT04191382Phase 2Updated Sep 18, 2025
Sponsor: Sanofi
Breast Cancer
United States, Belgium, France, Italy, Japan +4 more
Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and OlderCompleted
NCT04762680Phase 2, Phase 3Updated Sep 18, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
COVID-19
United States, Australia, France, Honduras, New Zealand +2 more
Dupilumab Skin Barrier Function Study in Atopic DermatitisCompleted
NCT04447417Phase 4Updated Sep 18, 2025
Sponsor: Sanofi
Atopic Dermatitis
United States, Canada
Study on a MenACYW Conjugate Vaccine Administered as a Single Dose in Participants Aged 12 Months and Older in VietnamCompleted
NCT06228586Phase 3Updated Sep 17, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningococcal Infection · Healthy Volunteers
Vietnam
Dose-finding Study for SAR442168 in Relapsing Multiple SclerosisCompleted
NCT03889639Phase 2Updated Sep 17, 2025
Sponsor: Sanofi
Relapsing Multiple Sclerosis
United States, Canada, Czechia, Estonia, France +5 more
Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)Completed
NCT04183335Phase 3Updated Sep 17, 2025
Sponsor: Sanofi
Neurodermatitis
United States, Argentina, China, France, Japan +3 more
China Post-marketing Surveillance (PMS) Study of Aldurazyme®Completed
NCT05134571Phase 4Updated Sep 17, 2025
Sponsor: Genzyme, a Sanofi Company
Mucopolysaccharidosis I
China
Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)Completed
NCT04202679Phase 3Updated Sep 17, 2025
Sponsor: Sanofi
Neurodermatitis
United States, Canada, Chile, France, Hungary +6 more
Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult SubjectsCompleted
NCT06064539Phase 1Updated Sep 17, 2025
Sponsor: Sanofi
Multiple Sclerosis
United States
Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and OlderTerminated
NCT04137887Phase 3Updated Sep 17, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza (Healthy Volunteers)
Finland
Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult SubjectsCompleted
NCT04451954Phase 1Updated Sep 17, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza Immunisation · Healthy Volunteers
United States
Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney TransplantationTerminated
NCT04294459Phase 1, Phase 2Updated Sep 17, 2025
Sponsor: Sanofi
Immune System Disorder
United States, Spain
Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and OlderCompleted
NCT04537208Phase 1, Phase 2Updated Sep 17, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
COVID-19 (Healthy Volunteers)
United States
Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With VenglustatTerminated
NCT04705051Phase 3Updated Sep 17, 2025
Sponsor: Sanofi
Congenital Cystic Kidney Disease
United States, Australia, Belgium, Germany, Japan +3 more

Previous page Next page